Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
The newly emerged Nashville Biosciences has the considerable genomics and bioinformatics resources of Vanderbilt behind it as it promotes new R&D techniques.
Armonica Technologies is looking to develop a nanochannel-based sequencing device that uses optical detection.
The startup aims to tap into the $60 billion probiotics industry by sequencing the microbiomes of athletes to identify bacteria that improve performance.
Researchers from the Netherlands Cancer Institute plan to spin out a company to use sequencing-based cellular network mapping to aid in drug development.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The firm is considering separating the point-of-care and lab test arms of its business, delisting its shares, and buying back stock from shareholders.
The UCSC spinout plans to launch a handheld nanopore sensor this year and will partner with diagnostic and other companies to develop assays.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more